AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2023
May 19, 2023
30016_dirs_2023-05-19_3add92b8-57ae-4a41-95d1-e6f0eaa98d78.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2023-05-17
Reporting Person: SAMAD SAM (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-05-17 | Non-Qualified Stock Option (right-to-buy) | $487.12 | A | 645 | Acquired | 2033-05-16 | Common Stock (645.0) | Direct |
| 2023-05-17 | Deferred Stock Unit | $ | A | 257 | Acquired | Common Stock (257.0) | Direct |
Footnotes
F1: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier.
F2: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.